← Back to Search

Monoclonal Antibodies

LY3471851 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Nektar Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose up to 56 days postdose
Awards & highlights

Study Summary

This study is evaluating whether a drug called LY3471851 can be safely administered under the skin.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose up to 56 days postdose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 56 days postdose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3471851
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3471851

Side effects data

From 2023 Phase 2 trial • 291 Patients • NCT04433585
16%
Injection site reaction
15%
Pyrexia
8%
Fatigue
7%
Nasopharyngitis
7%
Arthralgia
5%
Urinary tract infection
5%
Injection site erythema
5%
Injection site pain
5%
Alanine aminotransferase increased
5%
Anaemia
4%
COVID-19
4%
Bronchitis
4%
Injection site pruritus
4%
Asthenia
4%
Myalgia
4%
Pruritus
4%
Erythema
4%
Gamma-glutamyltransferase increased
3%
Pharyngitis
3%
Dyspepsia
3%
Pain in extremity
3%
Urticaria
3%
Rash
3%
Dermatitis contact
3%
Pityriasis rosea
3%
Influenza
3%
Pain
3%
Injection site rash
3%
Injection site swelling
3%
Nausea
3%
Back pain
3%
Headache
3%
Drug hypersensitivity
3%
Heavy menstrual bleeding
3%
Aspartate aminotransferase increased
1%
Vaccination complication
1%
Procedural pain
1%
Soft tissue injury
1%
Oedema peripheral
1%
Influenza like illness
1%
Swelling face
1%
Groin pain
1%
Limb injury
1%
Eosinophilia
1%
Iron deficiency anaemia
1%
Lymphadenitis
1%
Neutropenia
1%
Nasal obstruction
1%
Cough
1%
Nasal dryness
1%
Depression
1%
COVID-19 pneumonia
1%
Pyelonephritis
1%
Vomiting
1%
Chest pain
1%
Upper respiratory tract infection
1%
Furuncle
1%
Rhinitis
1%
Sinusitis
1%
Fungal infection
1%
Oral candidiasis
1%
Otitis externa
1%
Pharyngitis bacterial
1%
Viral infection
1%
Application site reaction
1%
Chills
1%
Feeling abnormal
1%
Injection site erosion
1%
Injection site exfoliation
1%
Injection site hypersensitivity
1%
Localised oedema
1%
Sensation of foreign body
1%
Diarrhoea
1%
Gastritis
1%
Dental caries
1%
Haemorrhoids
1%
Abdominal pain
1%
Mouth ulceration
1%
Oesophageal motility disorder
1%
Systemic lupus erythematosus
1%
Arthritis
1%
Neck pain
1%
Eczema
1%
Heart rate increased
1%
Urine protein/creatinine ratio increased
1%
Urinary sediment
1%
Dizziness
1%
Dysaesthesia
1%
Ophthalmic migraine
1%
Ligament sprain
1%
Joint dislocation
1%
Post procedural oedema
1%
Thermal burn
1%
Oropharyngeal pain
1%
Rhinorrhoea
1%
Hypotension
1%
Hot flush
1%
Delusion
1%
Seasonal allergy
1%
Myopia
1%
Dry eye
1%
Erythema of eyelid
1%
Vision blurred
1%
Bundle branch block right
1%
Vertigo
1%
Dysuria
1%
Pollakiuria
1%
Skin infection
1%
Rash maculo-papular
1%
Memory impairment
1%
Post procedural complication
1%
Hypertension
100%
80%
60%
40%
20%
0%
Study treatment Arm
LY3471851 High Dose
Placebo
LY3471851 Low Dose
LY3471851 Mid Dose

Trial Design

2Treatment groups
Experimental Treatment
Group I: LY3471851 (Thigh)Experimental Treatment1 Intervention
LY3471851 administered SC into the thigh.
Group II: LY3471851 (Abdomen)Experimental Treatment1 Intervention
LY3471851 administered subcutaneously (SC) into the abdomen.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3471851
2021
Completed Phase 2
~670

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Nektar TherapeuticsLead Sponsor
58 Previous Clinical Trials
10,271 Total Patients Enrolled
Eli Lilly and CompanyIndustry Sponsor
2,619 Previous Clinical Trials
3,206,528 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,347 Previous Clinical Trials
405,674 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Single-Dose Study of LY3471851 in Healthy Participants
2021. "A Single-Dose Study of LY3471851 in Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04998487.
~19 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top